An LC-MS/MS method for the quantitation of cabozantinib in rat plasma: Application to a pharmacokinetic study

Su, Qinghong; Li, Jian; Ji, Xiwei; Li, Jingyun; Zhou, Tianhang; Lu, Wei; Li, Liang

doi:10.1016/j.jchromb.2015.01.024

Cited by 21 publications

(20 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, one recent study reported AFB simultaneous determination with other TKIs namely, vandetanib, pazopanib, and dasatinib in human plasma using HPLC-DAD [14] with the AFB linearity range 0.7 -7.0 µgmL -1 , which is higher than its reported C max (maximum plasma concentration) value of 6.19 -7.58 ngmL -1 [11] and 11.6 -40.8 ngmL -1 after administration of single and multiple doses of different AFB concentrations [15]. On the other hand, individual CBZ quantification was reported using HPLC-UV [16], LC-MS/MS [17,18] in rat plasma with one study using micellar enhanced spectrofluorimetry in human plamsa [19].…”

Section: Introductionmentioning

confidence: 74%

Liquid chromatographic-tandem mass spectrometric assay for simultaneous quantitation of tofacitinib, cabozantinib and afatinib in human plasma and urine

Kadi¹,

Darwish²,

Attwa³

et al. 2017

Trop. J. Pharm Res

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 74%

Liquid chromatographic-tandem mass spectrometric assay for simultaneous quantitation of tofacitinib, cabozantinib and afatinib in human plasma and urine

Kadi¹,

Darwish²,

Attwa³

et al. 2017

Trop. J. Pharm Res

View full text Add to dashboard Cite

“…Accuracy and precision were calculated via relative standard deviation (RSD). For each QCs, the RSD values should be less than 15% [20]. The precision of an analytical procedure expresses the closeness of agreement between a series of measurements obtained from multiple sampling of the same homogeneous sample under the prescribed conditions.…”

Section: Methodsmentioning

confidence: 99%

Development of HPLC and LC–MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO

Schneider‐Futschik

Reyes-Ortega

Wilson

et al. 2016

Journal of Chromatography B

Self Cite

View full text Add to dashboard Cite

ORKAMBI (ivacaftor-lumacaftor [LUMA]) and KALYDECO (ivacaftor; IVA) are two new breakthrough cystic fibrosis (CF) drugs that directly modulate the activity and trafficking of the defective CFTR underlying the CF disease state. Currently, no therapeutic drug monitoring assays exist for these very expensive, albeit, important drugs. In this study, for the first time HPLC and LC-MS methods were developed and validated for rapid detection and quantification of IVA and its major metabolites hydroxymethyl-IVA M1 (active) and IVA-carboxylate M6 (inactive); and LUMA in the plasma and sputum of CF patients. With a mobile phase consisting of acetonitrile/water:0.1% formic acid (60:40 v/v) at a flow rate of 1 mL/min, a linear correlation was observed over a concentration range from 0.01 to 10 μg/mL in human plasma (IVA R2>0.999, IVA M1 R2> 0.9961, IVA M6 R2>0.9898, LUMA R2>0.9954). The assay was successfully utilized to quantify the concentration of LUMA, IVA, M1 and M6 in the plasma and sputum of CF patients undergoing therapy with KALYDECO (IVA 150 mg/q12 h) or ORKAMBI (200 mg/q12 h LUMA-125 mg/q12 h IVA). The KALYDECO patient exhibited an IVA plasma concentration of 0.97 μg/mL at 2.5 h post dosage. M1 and M6 plasma concentrations were 0.50 μg/mL and 0.16 μg/mL, respectively. Surprisingly, the ORKAMBI patient displayed very low plasma concentrations of IVA (0.06 μg/mL) and M1 (0.07 μg/mL). The M6 concentrations (0.15 μg/mL) were comparable to those of the KALYDECO patient. However, we observed a relatively high plasma concentration of LUMA (4.42 μg/mL). This reliable and novel method offers a simple and sensitive approach for therapeutic drug monitoring of KALYDECO and ORKAMBI in plasma and sputum. The introduction of the assay into the clinical setting will facilitate pharmacokinetics/pharmacodynamic analysis and assist clinicians to develop more cost effective and efficacious dosage regimens for these breakthrough CF drugs.

show abstract

“…These results indicated that PG was slowly absorbed into the circulatory blood system with low oral absolute bioavailability in vivo . It is well-known that drug absorption is a complicated process having a close relationship with physicochemical as well as physiological properties [16]. The molecular mass of PG is 1049.2 Da, which is larger than the favorable value (<500 Da), leading to poor ability to cross the lipid bilayer cell membrane.…”

Section: Resultsmentioning

confidence: 99%

A new quantitation method of protodioscin by HPLC–ESI-MS/MS in rat plasma and its application to the pharmacokinetic study

Zhang

Guo

et al. 2016

Steroids

View full text Add to dashboard Cite

A specific high performance liquid chromatography tandem mass spectrometry (HPLC–MS/MS method) was established for determining the concentration of protodioscin (PG) in rat plasma after intragastric administration of its standard form. Ginsenoside Rb1 was selected as the internal standard (IS). The plasma sample was prepared using one-step deproteinization procedure by adding three parts of acetonitrile to precipitate proteins. The chromatographic separation was accomplished on an Inersil ODS-3 C18 column (250 × 4.6 mm, 5 μm) with a mobile phase composed with acetonitrile and water containing 0.1% formic acid under a gradient elution mode at a flow rate of 1 mL min−1. A 3:1 portion of the eluent after a microsplit was detected on a triple quadrupole tandem mass spectrometer coupled with electrospray ionization (ESI) in positive ion and multiple reaction monitoring (MRM) scanning modes. The mass transitions were selected as 888.1 → 1050.2 for PG and 948.2 → 1110.3 for IS, respectively. After careful validation, the plasma samples were always stable under different storage conditions. These analytical results rendered sensitive, selective, and reliable values by this established method which displayed high accuracy, adequate extracted recoveries, and almost negligible matrix effects. This method was applied to the pharmacokinetic studies on PG level in the rat plasma and its pharmacokinetic effect. The results of our studies suggest that the present method may be a useful tool for further clinical study of PG.

show abstract

An LC-MS/MS method for the quantitation of cabozantinib in rat plasma: Application to a pharmacokinetic study

Cited by 21 publications

References 17 publications

Liquid chromatographic-tandem mass spectrometric assay for simultaneous quantitation of tofacitinib, cabozantinib and afatinib in human plasma and urine

Liquid chromatographic-tandem mass spectrometric assay for simultaneous quantitation of tofacitinib, cabozantinib and afatinib in human plasma and urine

Development of HPLC and LC–MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO

A new quantitation method of protodioscin by HPLC–ESI-MS/MS in rat plasma and its application to the pharmacokinetic study

Contact Info

Product

Resources

About